Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

882727

registered interest
date	13/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dermatitis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of adults with atopic dermatitis in (a) Penistone and Stocksbridge constituency, (b) England and (c) the UK.
tabling member constituency	Penistone and Stocksbridge
tabling member printed	Angela Smith
uin	135789
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>This data is not available, however, the National Institute for Health and Care Excellence estimates that atopic dermatitis (atopic eczema) is a common skin condition that affects between 2–10% of adults.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/04/2018 16:18:03 answering member 4067 label Biography information for Steve Brine
tabling member	1564 label Biography information for Angela Smith

882728

registered interest
date	13/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Skin Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure patients in England with (a) skin conditions and (b) atopic dermatitis are able to access to new innovative treatments.
tabling member constituency	Penistone and Stocksbridge
tabling member printed	Angela Smith
uin	135790
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. NICE has published a range of guidance products for the management of skin conditions, including technology appraisals, guidelines and quality standards, which can be accessed at the following link:</p><p> </p><p><a href="https://www.nice.org.uk/guidance/conditions-and-diseases/skin-conditions/skin-conditions--general-and-other#technology-appraisal-guidance" target="_blank">https://www.nice.org.uk/guidance/conditions-and-diseases/skin-conditions/skin-conditions--general-and-other#technology-appraisal-guidance</a></p><p> </p><p>National Health Service commissioners are legally required to fund treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>The Government takes the issue of ensuring rapid access to innovative therapies very seriously, which is why on 3 November 2017, we published our response to the Accelerated Access Review. We set out plans to give patients quicker access to life-changing treatments and make the United Kingdom the best place in the world for industry to invest and innovate.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/04/2018 15:39:05 answering member 4067 label Biography information for Steve Brine
tabling member	1564 label Biography information for Angela Smith

882729

registered interest
date	13/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in ensuring that patients have access to promising and innovative medicines as early as possible.
tabling member constituency	Penistone and Stocksbridge
tabling member printed	Angela Smith
uin	135791
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>Since the Early Access to Medicines Scheme (EAMS) was launched in 2014, the Medicines and Healthcare products Regulatory Agency has awarded 50 promising innovative medicines designations and 21 positive scientific opinions as part of the scheme. NHS England records show that 1,100 patients in England have accessed treatment through EAMS.</p><p> </p><p>Since the publication of the independent review of the EAMS the Government has made a number of improvements. Partners have worked together to provide updated guidance on the benefits and entry requirements for EAMS and are developing further guidance on collecting real world data in the National Health Service to further inform value assessment in a National Institute for Health and Care Excellence appraisal.</p><p> </p><p>We have also established the EAMS task group to provide a forum for industry to engage and make suggestions to the Government, the devolved administrations and arm’s length bodies regarding EAMS as per the recommendations of the 2016 review.</p><p> </p><p>We are also applying the learning from EAMs to the development of the Accelerated Access Pathway. Due to launch shortly, this will be a streamlined route to market which will help get the most innovative treatments to patients faster.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/04/2018 15:38:08 answering member 4067 label Biography information for Steve Brine
tabling member	1564 label Biography information for Angela Smith

882730

registered interest
date	13/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in encouraging pharmaceutical companies to launch promising and innovative medicines in the UK.
tabling member constituency	Penistone and Stocksbridge
tabling member printed	Angela Smith
uin	135792
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>The Life Sciences Industrial Strategy set out our vision of being a world-leader in developing and bringing to market innovative medicines to improve life-chances of United Kingdom patients. It highlighted the importance of evolving and simplifying the access system for new medicines by implementing, and building on, the findings of the Accelerated Access Review.</p><p> </p><p>The Early Access to Medicines Scheme (EAMS) is an essential part of delivering on this ambition. It has been effective in encouraging companies to bring their products to the UK and market them. The figures below show increasing engagement from industry as the scheme has progressed.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>Number of Promising Innovative Medicines awarded</p></td><td><p>8</p></td><td><p>6</p></td><td><p>17</p></td><td><p>20</p></td></tr><tr><td><p>Number of Scientific Opinions awarded</p></td><td><p>1</p></td><td><p>8</p></td><td><p>3</p></td><td><p>7</p></td></tr></tbody></table><p> </p><p>The EAMS task group has been established to provide a forum for industry to engage with the Government, the devolved administrations and arm’s length bodies, driving further improvements to the scheme and making the UK a more attractive place to test and deliver new pharmaceuticals.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/04/2018 15:40:30 answering member 4067 label Biography information for Steve Brine
tabling member	1564 label Biography information for Angela Smith